Company intelligence / Profile preview
Synbiotic Health
- Ownership
- Private
- Development stage
- Commercial
Overview
Synbiotic Health develops advanced probiotic and synbiotic ingredients based on deep microbiome research. Their lead product, iVS‑1®, has demonstrated superior gut colonization compared to competitors and supports gut barrier integrity. Multiple strains are advancing through preclinical development with several selected for human clinical trials. The company’s approach emphasizes ecological compatibility within the gut microbiome ecosystem.
- Therapeutic areas
- GastroenterologyOther
- Modalities
- ProbioticsSynbiotics (probiotic + prebiotic combinations)
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Synbiotic Health.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Synbiotic Health.